Prostate health index (PHI) as a reliable biomarker for prostate cancer: a systematic review and meta-analysis.
PCa
biomarker
clinically significant prostate cancer (csPCa)
diagnosis
prostate health index (PHI)
prostate tumor
screening
Journal
Clinical chemistry and laboratory medicine
ISSN: 1437-4331
Titre abrégé: Clin Chem Lab Med
Pays: Germany
ID NLM: 9806306
Informations de publication
Date de publication:
26 07 2022
26 07 2022
Historique:
received:
12
04
2022
accepted:
03
05
2022
pubmed:
15
5
2022
medline:
22
6
2022
entrez:
14
5
2022
Statut:
epublish
Résumé
Prostate cancer (PCa) represents the second most common solid cancer in men worldwide. In the last decades, the prostate health index (PHI) emerged as a reliable biomarker for detecting PCa and differentiating between non-aggressive and aggressive forms. However, before introducing it in clinical practice, more evidence is required. Thus, we performed a systematic review and meta-analysis for assessing the diagnostic performance of PHI for PCa and for detecting clinically significant PCa (csPCa). Relevant publications were identified by a systematic literature search on PubMed and Web of Science from inception to January 11, 2022. Sixty studies, including 14,255 individuals, met the inclusion criteria for our meta-analysis. The pooled sensitivity and specificity of PHI for PCa detection was 0.791 (95%CI 0.739-0.834) and 0.625 (95%CI 0.560-0.686), respectively. The pooled sensitivity and specificity of PHI for csPCa detection was 0.874 (95%CI 0.803-0.923) and 0.569 (95%CI 0.458-0.674), respectively. Additionally, the diagnostic odds ratio was 6.302 and 9.206, respectively, for PCa and csPCa detection, suggesting moderate to good effectiveness of PHI as a diagnostic test. PHI has a high accuracy for detecting PCa and discriminating between aggressive and non-aggressive PCa. Thus, it could be useful as a biomarker in predicting patients harbouring more aggressive cancer and guiding biopsy decisions.
Identifiants
pubmed: 35567430
pii: cclm-2022-0354
doi: 10.1515/cclm-2022-0354
doi:
Substances chimiques
Biomarkers
0
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1261-1277Informations de copyright
© 2022 Luisa Agnello et al., published by De Gruyter, Berlin/Boston.
Références
EU Science Hub. Cancer incidence and mortality in EU-27 countries; 2020. Available from: https://ec.europa.eu/jrc/en/news/2020-cancer-incidence-and-mortality-eu-27-countries.
Klotz, L. Low-risk prostate cancer can and should often be managed with active surveillance and selective delayed intervention. Nat Clin Pract Urol 2008;5:2–3. https://doi.org/10.1038/ncpuro0993.
Haas, GP, Delongchamps, N, Brawley, OW, Wang, CY, de la Roza, G. The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. Can J Urol 2008;15:3866–71.
McGrath, S, Christidis, D, Perera, M, Hong, SK, Manning, T, Vela, I, et al.. Prostate cancer biomarkers: are we hitting the mark? Prostate Int 2016;4:130–5. https://doi.org/10.1016/j.prnil.2016.07.002.
US Preventive Services Task Force, Grossman, DC, Curry, SJ, Owens, DK, Bibbins-Domingo, K, Caughey, AB, Davidson, KW, et al.. Screening for prostate cancer: US preventive services task force recommendation statement. JAMA 2018;319:1901–13. https://doi.org/10.1001/jama.2018.3710.
Sharma, S, Zapatero-Rodríguez, J, O’Kennedy, R. Prostate cancer diagnostics: clinical challenges and the ongoing need for disruptive and effective diagnostic tools. Biotechnol Adv 2017;35:135–49. https://doi.org/10.1016/j.biotechadv.2016.11.009.
Lilja, H, Christensson, A, Dahlén, U, Matikainen, MT, Nilsson, O, Pettersson, K, et al.. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem 1991;37:1618–25. https://doi.org/10.1093/clinchem/37.9.1618.
Stenman, UH, Leinonen, J, Alfthan, H, Rannikko, S, Tuhkanen, K, Alfthan, O. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991;51:222–6.
Mikolajczyk, SD, Catalona, WJ, Evans, CL, Linton, HJ, Millar, LS, Marker, KM, et al.. Proenzyme forms of prostatespecifc antigen in serum improve the detection of prostate cancer. Clin Chem 2004;50:1017–25. https://doi.org/10.1373/clinchem.2003.026823.
Ferro, M, De Cobelli, O, Lucarelli, G, Porreca, A, Busetto, GM, Cantiello, F, et al.. Beyond PSA: the role of prostate health index (phi). Int J Mol Sci 2020;21:1184. https://doi.org/10.3390/ijms21041184.
Lepor, A, Catalona, WJ, Loeb, S. The prostate health index: its utility in prostate cancer detection. Urol Clin North Am 2016;43:1–6. https://doi.org/10.1016/j.ucl.2015.08.001.
Stephan, C, Vincendeau, S, Houlgatte, A, Cammann, H, Jung, K, Semjonow, A. Multicenter evaluation of [−2] proprostate-specific antigen and the prostate health index for detecting prostate cancer. Clin Chem 2013;59:306–14. https://doi.org/10.1373/clinchem.2012.195784.
European Association of Urology. EAU guidelines: prostate cancer: Uroweb; 2022. Available from: https://uroweb.org/guideline/prostate-cancer/#5.
American Urological Association. Prostate cancer: early detection guideline – American urological association; 2013. Available from: https://www.auanet.org/guidelines/prostate-cancer-early-detection-guideline.
Page, MJ, McKenzie, JE, Bossuyt, PM, Boutron, I, Hoffmann, TC, Mulrow, CD, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. PLoS Med 2021;18:e1003583. https://doi.org/10.1371/journal.pmed.1003583.
Hamza, TH, van Houwelingen, HC, Stijnen, T. The binomial distribution of meta-analysis was preferred to model within-study variability. J Clin Epidemiol 2008;61:41–51. https://doi.org/10.1016/j.jclinepi.2007.03.016.
Jackson, D, Law, M, Stijnen, T, Viechtbauer, W, White, IR. A comparison of seven random-effects models for meta-analyses that estimate the summary odds ratio. Stat Med 2018;37:1059–85. https://doi.org/10.1002/sim.7588.
Chu, H, Cole, SR. Bivariate meta-analysis of sensitivity and specificity with sparse data: a generalized linear mixed model approach. J Clin Epidemiol 2006;59:1331–2. https://doi.org/10.1016/j.jclinepi.2006.06.011.
Software for meta-analysis of DTA studies; 2012. Available from: https://methods.cochrane.org/sdt/software-meta-analysis-dta-studies [Accessed 5 Feb 2022].
Patel, A, Cooper, NJ, Freeman, SC, Sutton, AJ. Graphical enhancements to summary receiver operating characteristic plots to facilitate the analysis and reporting of meta-analysis of diagnostic test accuracy data. Res Synth Methods 2021;12:34–44. https://doi.org/10.1002/jrsm.1439.
Freeman, SC, Kerby, CR, Patel, A, Cooper, NJ, Quinn, T, Sutton, AJ. Development of an interactive web-based tool to conduct and interrogate meta-analysis of diagnostic test accuracy studies: MetaDTA. BMC Med Res Methodol 2019;81:1–11. https://doi.org/10.1186/s12874-019-0724-x.
Arends, LR, Hamza, TH, van Houwelingen, JC, Heijenbrok-Kal, MH, Hunink, MG, Stijnen, T. Bivariate random effects meta-analysis of ROC curves. Med Decis Making 2008;28:621–38. https://doi.org/10.1177/0272989x08319957.
Phillips, B, Stewart, LA, Sutton, AJ. ‘Cross hairs’ plots for diagnostic meta-analysis. Res Synth Methods 2010;1:308–15. https://doi.org/10.1002/jrsm.26.
Chiu, ST, Cheng, YT, Pu, YS, Lu, YC, Hong, JH, Chung, SD, et al.. Prostate health index density outperforms prostate health index in clinically significant prostate cancer detection. Front Oncol 2021;11:772182. https://doi.org/10.3389/fonc.2021.772182.
Ferro, M, Crocetto, F, Bruzzese, D, Imbriaco, M, Fusco, F, Longo, N, et al.. Prostate health index and multiparametric MRI: partners in crime fighting overdiagnosis and overtreatment in prostate cancer. Cancers 2021;13:4723. https://doi.org/10.3390/cancers13184723.
Garrido, MM, Marta, JC, Bernardino, RM, Guerra, J, Fernandes, F, Pereira, MH, et al.. The percentage of [−2] pro-prostate-specific antigen and the prostate health index outperform prostate-specific antigen and the percentage of free prostate-specific antigen in the detection of clinically significant prostate cancer and can be used as reflex tests. Arch Pathol Lab Med 2021. https://doi.org/10.5858/arpa.2021-0079-OA.
Stejskal, J, Adamcová, V, Záleský, M, Novák, V, Čapoun, O, Fiala, V, et al.. The predictive value of the prostate health index vs. multiparametric magnetic resonance imaging for prostate cancer diagnosis in prostate biopsy. World J Urol 2021;39:1889–95. https://doi.org/10.1007/s00345-020-03397-4.
Kim, L, Boxall, N, George, A, Burling, K, Acher, P, Aning, J, et al.. Clinical utility and cost modelling of the phi test to triage referrals into image-based diagnostic services for suspected prostate cancer: the PRIM (Phi to RefIne Mri) study. BMC Med 2020;18:95. https://doi.org/10.1186/s12916-020-01548-3.
Nassir, AM, Kamel, HFM. Explication of the roles of prostate health index (PHI) and urokinase plasminogen activator (uPA) as diagnostic and predictor tools for prostate cancer in equivocal PSA range of 4–10 ng/mL. Saudi J Biol Sci 2020;27:1975–84. https://doi.org/10.1016/j.sjbs.2020.04.004.
Othman, H, Yamin, AHA, Isa, ND, Bahadzor, B, Zakaria, SZS. Diagnostic performance of prostate health index (PHI) in predicting prostate cancer on prostate biopsy. Malays J Pathol 2020;42:209–14.
Barisiene, M, Bakavicius, A, Stanciute, D, Jurkeviciene, J, Zelvys, A, Ulys, A, et al.. Prostate health index and prostate health index density as diagnostic tools for improved prostate cancer detection. BioMed Res Int 2020;2020:9872146. https://doi.org/10.1155/2020/9872146.
Ito, K, Yokomizo, A, Tokunaga, S, Arai, G, Sugimoto, M, Akakura, K, et al.. Diagnostic impacts of clinical laboratory based p2PSA indexes on any grade, gleason grade group 2 or greater, or 3 or greater prostate cancer and prostate specific antigen below 10 ng/mL. J Urol 2020;203:83–91. https://doi.org/10.1097/ju.0000000000000495.
Kopecký, J, Navláčilová, V, Janoutová, J, Janout, V. Epidemiological study on more accurate diagnosis of prostate cancer. Cent Eur J Publ Health 2020;28:65–9.
Stojadinovic, M, Vukovic, I, Ivanovic, M, Stojadinovic, M, Milovanovic, D, Pantic, D, et al.. Optimal threshold of the prostate health index in predicting aggressive prostate cancer using predefined cost-benefit ratios and prevalence. Int Urol Nephrol 2020;52:893–901. https://doi.org/10.1007/s11255-019-02367-z.
Hsieh, PF, Li, WJ, Lin, WC, Chang, H, Chang, CH, Huang, CP, et al.. Combining prostate health index and multiparametric magnetic resonance imaging in the diagnosis of clinically significant prostate cancer in an Asian population. World J Urol 2020;38:1207–14. https://doi.org/10.1007/s00345-019-02889-2.
Vendrami, CL, McCarthy, RJ, Chatterjee, A, Casalino, D, Schaeffer, EM, Catalona, WJ, et al.. The utility of prostate specific antigen density, prostate health index, and prostate health index density in predicting positive prostate biopsy outcome is dependent on the prostate biopsy methods. Urol 2019;129:153–9. https://doi.org/10.1016/j.urology.2019.03.018.
Jagarlamudi, KK, Zupan, M, Kumer, K, Fabjan, T, Hlebič, G, Eriksson, S, et al.. The combination of AroCell TK 210 ELISA with prostate health index or prostate-specific antigen density can improve the ability to differentiate prostate cancer from noncancerous conditions. Prostate 2019;79:856–63. https://doi.org/10.1002/pros.23791.
Cheng, YT, Chiang, CH, Pu, YS, Liu, SP, Lu, YC, Chang, YK, et al.. The application of p2PSA% and prostate health index in prostate cancer detection: a prospective cohort in a Tertiary Medical Center. J Formos Med 2019;118:260–7. https://doi.org/10.1016/j.jfma.2018.05.001.
Sriplakich, S, Lojanapiwat, B, Chongruksut, W, Phuriyaphan, S, Kitirattakarn, P, Jun-Ou, J, et al.. Prospective performance of the prostate health index in prostate cancer detection in the first prostate biopsy of men with a total prostatic specific antigen of 4–10 ng/mL and negative digital rectal examination. Prostate Int 2018;6:136–9. https://doi.org/10.1016/j.prnil.2018.02.002.
Hsieh, PF, Chang, CH, Yang, CR, Huang, CP, Chen, WC, Yeh, CC, et al.. Prostate health index (PHI) improves prostate cancer detection at initial biopsy in Taiwanese men with PSA 4–10 ng/mL. Kaohsiung J Med Sci 2018;34:461–6. https://doi.org/10.1016/j.kjms.2018.02.007.
Dolejsova, O, Kucera, R, Fuchsova, R, Topolcan, O, Svobodova, H, Hes, O, et al.. The ability of prostate health index (PHI) to predict gleason score in patients with prostate cancer and discriminate patients between gleason score 6 and gleason score higher than 6-A study on 320 patients after radical prostatectomy. Technol Cancer Res Treat 2018;17. https://doi.org/10.1177/1533033818787377.
Park, H, Lee, SW, Song, G, Kang, TW, Jung, JH, Chung, HC, et al.. Diagnostic performance of %[−2]proPSA and prostate health index for prostate cancer: prospective, multi-institutional study. J Korean Med Sci 2018;33:e94. https://doi.org/10.3346/jkms.2018.33.e94.
Al Saidi, SS, Al Riyami, NB, Al Marhoon, MS, Al Saraf, MS, Al Busaidi, SS, Bayoumi, R, et al.. Validity of prostate health index and percentage of [−2] pro-prostate-specific antigen as novel biomarkers in the diagnosis of prostate cancer: Omani tertiary hospitals experience. Oman Med J 2017;32:275–83. https://doi.org/10.5001/omj.2017.55.
Na, R, Ye, D, Qi, J, Liu, F, Helfand, BT, Brendler, CB, et al.. Prostate health index significantly reduced unnecessary prostate biopsies in patients with PSA 2–10 ng/mL and PSA >10 ng/mL: results from a Multicenter Study in China. Prostate 2017;77:1221–9. https://doi.org/10.1002/pros.23382.
Vukovic, I, Djordjevic, D, Bojanic, N, Babic, U, Soldatovic, I. Predictive value of [−2]propsa (p2psa) and its derivatives for the prostate cancer detection in the 2.0 to 10.0ng/mL PSA range. Int Braz J Urol 2017;43:48–56. https://doi.org/10.1590/s1677-5538.ibju.2016.0256.
Furuya, K, Kawahara, T, Narahara, M, Tokita, T, Fukui, S, Imano, M, et al.. Measurement of serum isoform [−2]proPSA derivatives shows superior accuracy to magnetic resonance imaging in the diagnosis of prostate cancer in patients with a total prostate-specific antigen level of 2–10 ng/mL. Scand J Urol 2017;51:251–7. https://doi.org/10.1080/21681805.2017.1298155.
Friedl, A, Stangl, K, Bauer, W, Kivaranovic, D, Schneeweiss, J, Susani, M, et al.. Prostate-specific antigen parameters and prostate health index enhance prostate cancer prediction with the in-bore 3-T magnetic resonance imaging-guided transrectal targeted prostate biopsy after negative 12-core biopsy. Urol 2017;110:148–53. https://doi.org/10.1016/j.urology.2017.08.019.
Tan, TW, Png, KS, Lee, CH, Yuwono, A, Yeow, Y, Chong, KT, et al.. MRI fusion-targeted transrectal prostate biopsy and the role of prostate-specific antigen density and prostate health index for the detection of clinically significant prostate cancer in southeast Asian men. J Endourol 2017;31:1111–6. https://doi.org/10.1089/end.2017.0485.
Tan, LG, Tan, YK, Tai, BC, Tan, KM, Gauhar, V, Tiong, HY, et al.. Prospective validation of %p2PSA and the prostate health index, in prostate cancer detection in initial prostate biopsies of Asian men, with total PSA 4–10 ng mL−1. Asian J Androl 2017;19:286–90. https://doi.org/10.4103/1008-682X.168687.
Chiu, PK, Teoh, JY, Lee, WM, Yee, CH, Chan, ES, Hou, SM, et al.. Extended use of prostate health index and percentage of [−2]pro-prostate-specific antigen in Chinese men with prostate specific antigen 10–20 ng/mL and normal digital rectal examination. Investig Clin Urol 2016;57:336–42. https://doi.org/10.4111/icu.2016.57.5.336.
Morote, J, Celma, A, Planas, J, Placer, J, Ferrer, R, de Torres, I, et al.. Diagnostic accuracy of prostate health index to identify aggressive prostate cancer. An institutional validation study. Actas Urol Esp 2016;40:378–85. https://doi.org/10.1016/j.acuroe.2016.05.005.
Lazzeri, M, Lughezzani, G, Haese, A, McNicholas, T, de la Taille, A, Buffi, NM, et al.. Clinical performance of prostate health index in men with tPSA>10ng/mL: results from a multicentric European study. Urol Oncol 2016;34:415.e13–9. https://doi.org/10.1016/j.urolonc.2016.04.003.
Yu, GP, Na, R, Ye, DW, Qi, J, Liu, F, Chen, HT, et al.. Performance of the prostate health index in predicting prostate biopsy outcomes among men with a negative digital rectal examination and transrectal ultrasonography. Asian J Androl 2016;18:633–8. https://doi.org/10.4103/1008-682X.172823.
Fuchsova, R, Topolcan, O, Windrichova, J, Hora, M, Dolejsova, O, Pecen, L, et al.. PHI in the early detection of prostate cancer. Anticancer Res 2015;35:4855–7.
Mearini, L, Nunzi, E, Ferri, C, Bellezza, G, Lolli, C, Porrozzi, C, et al.. Use of the prostate health index for the detection of aggressive prostate cancer at radical prostatectomy. Urol Int 2015;95:390–9. https://doi.org/10.1159/000379758.
Loeb, S, Sanda, MG, Broyles, DL, Shin, SS, Bangma, CH, Wei, JT, et al.. The prostate health index selectively identifies clinically significant prostate cancer. J Urol 2015;193:1163–9. https://doi.org/10.1016/j.juro.2014.10.121.
Seisen, T, Rouprêt, M, Brault, D, Léon, P, Cancel-Tassin, G, Compérat, E, et al.. Accuracy of the prostate health index versus the urinary prostate cancer antigen 3 score to predict overall and significant prostate cancer at initial biopsy. Prostate 2015;75:103–11. https://doi.org/10.1002/pros.22898.
Fossati, N, Buffi, NM, Haese, A, Stephan, C, Larcher, A, McNicholas, T, et al.. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer: results from a multicentric European prospective study. Eur Urol 2015;68:132–8. https://doi.org/10.1016/j.eururo.2014.07.034.
Mearini, L, Ferri, C, Lazzeri, M, Bini, V, Nunzi, E, Fiorini, D, et al.. Evaluation of prostate-specific antigen isoform p2PSA and its derivates, %p2PSA, prostate health index and prostate dimension-adjusted related index in the detection of prostate cancer at first biopsy: an exploratory, prospective study. Urol Int 2014;93:135–45. https://doi.org/10.1159/000356240.
Filella, X, Foj, L, Augé, JM, Molina, R, Alcover, J. Clinical utility of %p2PSA and prostate health index in the detection of prostate cancer. Clin Chem Lab Med 2014;52:1347–55. https://doi.org/10.1515/cclm-2014-0027.
Porpiglia, F, Russo, F, Manfredi, M, Mele, F, Fiori, C, Bollito, E, et al.. The roles of multiparametric magnetic resonance imaging, PCA3 and prostate health index-which is the best predictor of prostate cancer after a negative biopsy? J Urol 2014;192:60–6. https://doi.org/10.1016/j.juro.2014.01.030.
Ng, CF, Chiu, PK, Lam, NY, Lam, HC, Lee, KW, Hou, SS. The prostate health index in predicting initial prostate biopsy outcomes in Asian men with prostate-specific antigen levels of 4–10 ng/mL. Int Urol Nephrol 2014;46:711–7. https://doi.org/10.1007/s11255-013-0582-0.
Lazzeri, M, Abrate, A, Lughezzani, G, Gadda, GM, Freschi, M, Mistretta, F, et al.. Relationship of chronic histologic prostatic inflammation in biopsy specimens with serum isoform [−2]proPSA (p2PSA), %p2PSA, and prostate health index in men with a total prostate-specific antigen of 4–10 ng/mL and normal digital rectal examination. Urol 2014;83:606–12. https://doi.org/10.1016/j.urology.2013.10.016.
Scattoni, V, Lazzeri, M, Lughezzani, G, Luca, SD, Passera, R, Bollito, E, et al.. Head-to-head comparison of prostate health index and urinary PCA3 for predicting cancer at initial or repeat biopsy. J Urol 2013;190:496–501. https://doi.org/10.1016/j.juro.2013.02.3184.
Ferro, M, Bruzzese, D, Perdonà, S, Marino, A, Mazzarella, C, Perruolo, G, et al.. Prostate health index (Phi) and prostate cancer antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2–10 ng/mL. PLoS One 2013;8:e67687. https://doi.org/10.1371/journal.pone.0067687.
Lazzeri, M, Haese, A, Abrate, A, de la Taille, A, Redorta, JP, McNicholas, T, et al.. Clinical performance of serum prostate-specific antigen isoform [−2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project. BJU Int 2013;112:313–21. https://doi.org/10.1111/bju.12217.
Stephan, C, Vincendeau, S, Houlgatte, A, Cammann, H, Jung, K, Semjonow, A. Multicenter evaluation of [−2]proprostate-specific antigen and the prostate health index for detecting prostate cancer. Clin Chem 2013;59:306–14. https://doi.org/10.1373/clinchem.2012.195784.
Stephan, C, Jung, K, Semjonow, A, Schulze-Forster, K, Cammann, H, Hu, X, et al.. Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [−2]proprostate-specific antigen-based prostate health index for detection of prostate cancer. Clin Chem 2013;59:280–8. https://doi.org/10.1373/clinchem.2012.195560.
Perdonà, S, Bruzzese, D, Ferro, M, Autorino, R, Marino, A, Mazzarella, C, et al.. Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy. Prostate 2013;73:227–35. https://doi.org/10.1002/pros.22561.
Ferro, M, Bruzzese, D, Perdonà, S, Mazzarella, C, Marino, A, Sorrentino, A, et al.. Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers. Clin Chim Acta 2012;413:1274–8. https://doi.org/10.1016/j.cca.2012.04.017.
Guazzoni, G, Nava, L, Lazzeri, M, Scattoni, V, Lughezzani, G, Maccagnano, C, et al.. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/mL: results of a prospective study in a clinical setting. Eur Urol 2011;60:214–22. https://doi.org/10.1016/j.eururo.2011.03.052.
Liang, Y, Ankerst, DP, Ketchum, NS, Ercole, B, Shah, G, Shaughnessy, JDJr, et al.. Prospective evaluation of operating characteristics of prostate cancer detection biomarkers. J Urol 2011;185:104–10. https://doi.org/10.1016/j.juro.2010.08.088.
Mottet, N, van den Bergh, RCN, Briers, E, Van den Broeck, T, Cumberbatch, MG, Santis, MD, et al.. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 2021;79:243–62. https://doi.org/10.1016/j.eururo.2020.09.042.
Grey, AD, Chana, MS, Popert, R, Wolfe, K, Liyanage, SH, Acher, PL. Diagnostic accuracy of magnetic resonance imaging (MRI) prostate imaging reporting and data system (PI-RADS) scoring in a transperineal prostate biopsy setting. BJU Int 2015;115:728–35. https://doi.org/10.1111/bju.12862.
Santoro, AA, Gianfrancesco, LD, Racioppi, M, Pinto, F, Palermo, G, Sacco, E, et al.. Multiparametric magnetic resonance imaging of the prostate: lights and shadows. Urologia 2021;88:280–6. https://doi.org/10.1177/03915603211019982.
Rapisarda, S, Bada, M, Crocetto, F, Barone, B, Arcaniolo, D, Polara, A, et al.. The role of multiparametric resonance and biopsy in prostate cancer detection: comparison with definitive histological report after laparoscopic/robotic radical prostatectomy. Abdom Radiol (NY) 2020;45:4178–84. https://doi.org/10.1007/s00261-020-02798-8.
Massanova, M, Robertson, S, Barone, B, Dutto, L, Caputo, VF, Bhatt, JR, et al.. The comparison of imaging and clinical methods to estimate prostate volume: a single-centre retrospective study. Urol Int 2021;105:804–10. https://doi.org/10.1159/000516681.
Guazzoni, G, Lazzeri, M, Nava, L, Lughezzani, G, Larcher, A, Scattoni, V, et al.. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer. Eur Urol 2012;61:455–66. https://doi.org/10.1016/j.eururo.2011.10.038.
Tosoian, JJ, Druskin, SC, Andreas, D, Mullane, P, Chappidi, M, Joo, S, et al.. Prostate health index density improves detection of clinically significant prostate cancer. BJU Int 2017;120:793–8. https://doi.org/10.1111/bju.13762.
Lughezzani, G, Lazzeri, M, Buffi, NM, Abrate, A, Mistretta, FA, Hurle, R, et al.. Preoperative prostate health index is an independent predictor of early biochemical recurrence after radical prostatectomy: results from a prospective single-center study. Urol Oncol 2015;33:337.e7–14. https://doi.org/10.1016/j.urolonc.2015.05.007.
Maxeiner, A, Kilic, E, Matalon, J, Friedersdorff, F, Miller, K, Jung, K, et al.. The prostate health index PHI predicts oncological outcome and biochemical recurrence after radical prostatectomy – analysis in 437 patients. Oncotarget 2017;8:79279–88. https://doi.org/10.18632/oncotarget.17476.
Foj, L, Filella, X. Development and internal validation of a novel PHI-nomogram to identify aggressive prostate cancer. Clin Chim Acta 2020;501:174–8. https://doi.org/10.1016/j.cca.2019.10.039.
Stenner, E, Micheli, W, Bussani, A, Gotti, A, Biasioli, B. Comparison of Hybritech and WHO standardization applied to access hybritech total PSA assay on UniCel®. IJLaM 2008;4:43–6.
Bouttell, J, Teoh, J, Chiu, PK, Chan, KS, Ng, CF, Heggie, R, et al.. Economic evaluation of the introduction of the prostate health index as a rule-out test to avoid unnecessary biopsies in men with prostate specific antigen levels of 4–10 in Hong Kong. PLoS One 2019;14:e0215279. https://doi.org/10.1371/journal.pone.0215279.
Filella, X, Foj, L, Alcover, J, Augé, JM, Molina, R, Jiménez, W. The influence of prostate volume in prostate health index performance in patients with total PSA lower than 10 μg/L. Clin Chim Acta 2014;436:303–7. https://doi.org/10.1016/j.cca.2014.06.019.
Mearini, L, Ferri, C, Lazzeri, M, Bini, V, Nunzi, E, Fiorini, D, et al.. Evaluation of prostate-specific antigen isoform p2PSA and its derivates, %p2PSA, prostate health index and prostate dimension-adjusted related index in the detection of prostate cancer at first biopsy: an exploratory, prospective study. Urol Int 2014;93:135–45. https://doi.org/10.1159/000356240.
Friedl, A, Stangl, K, Bauer, W, Kivaranovic, D, Schneeweiss, J, Susani, M, et al.. Prostate-specific antigen parameters and prostate health index enhance prostate cancer prediction with the in-bore 3-T magnetic resonance imaging-guided transrectal targeted prostate biopsy after negative 12-core biopsy. Urol 2017;110:148–53. https://doi.org/10.1016/j.urology.2017.08.019.
Stephan, C, Jung, K, Lein, M, Rochow, H, Friedersdorff, F, Maxeiner, A. PHI density prospectively improves prostate cancer detection. World J Urol 2021;39:3273–9. https://doi.org/10.1007/s00345-020-03585-2.